Merck says cyber attack halted production, will hurt profits
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
July 31, 2017 9:41 AM EDTMerck (NYSE: MRK) (known as MSD outside the United States and Canada), through a wholly-owned subsidiary today announced that through a collaboration agreement with Generex Biotechnology Corporation and its wholly-owned subsidiary, Antigen Express, Inc has entered into a clinical trial to evaluate Antigens AE37 cancer vaccine in combination with Mercks anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.
The combination of AE37 plus KEYTRUDA follows previous studies, in which both... More
